Lipoprotein apheresis reduces major adverse cardiovascular event incidence in high-lipoprotein (a) subjects on proprotein convertase subtilisin/kexin type 9 inhibitor therapy

Journal Article Corrected proof Lipoprotein apheresis reduces major adverse cardiovascular event incidence in high-lipoprotein (a) subjects on proprotein convertase subtilisin/kexin type 9 inhibitor therapy Get access Francesco Sbrana, Francesco Sbrana U.O. Lipoapheresis and Center for Inherited Dyslipidemias, Fondazione Toscana Gabriele Monasterio, Via Moruzzi, Pisa 1—56124, Italy Corresponding author. Tel: +39 050 3153396, Email: francesco.sbrana@ftgm.it https://orcid.org/0000-0003-4607-0373 Search for other works by this author on: Oxford Academic Google Scholar Federico Bigazzi, Federico Bigazzi U.O. Lipoapheresis and Center for Inherited Dyslipidemias, Fondazione Toscana Gabriele Monasterio, Via Moruzzi, Pisa 1—56124, Italy Search for other works by this author on: Oxford Academic Google Scholar Carmen Corciulo, Carmen Corciulo U.O. Lipoapheresis and Center for Inherited Dyslipidemias, Fondazione Toscana Gabriele Monasterio, Via Moruzzi, Pisa 1—56124, Italy Search for other works by this author on: Oxford Academic Google Scholar Beatrice Dal Pino Beatrice Dal Pino U.O. Lipoapheresis and Center for Inherited Dyslipidemias, Fondazione Toscana Gabriele Monasterio, Via Moruzzi, Pisa 1—56124, Italy Search for other works by this author on: Oxford Academic Google Scholar European Journal of Preventive Cardiology, zwae054, https://doi.org/10.1093/eurjpc/zwae054 Published: 12 March 2024 Article history Received: 01 September 2023 Revision received: 07 December 2023 Accepted: 07 February 2024 Corrected and typeset: 12 March 2024 Published: 12 March 2024